The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2

REFERENCES

1. 1.↵
   2. Scherfler C,
   3. Schwarz J,
   4. Antonini A, et al

   . Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007;22:1229–38

   CrossRefPubMed
2. 2.↵
   2. Catafau AM,
   3. Tolosa E

   . Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 2004;19:1175–82

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Quinn N

   . Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989(suppl):78–89
4. 4.↵
   2. Papp MI,
   3. Lantos PL

   . The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235–43

   Abstract/FREE Full Text
5. 5.↵
   2. Schrag A,
   3. Good CD,
   4. Miszkiel K, et al

   . Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697–702

   CrossRef
6. 6.↵
   2. Nicoletti G,
   3. Fera F,
   4. Condino F, et al

   . MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease. Radiology 2006;239:825–30

   CrossRefPubMed
7. 7.↵
   2. Ghaemi M,
   3. Hilker R,
   4. Rudolf J, et al

   . Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET. J Neurol Neurosurg Psychiatry 2002;73:517–23

   Abstract/FREE Full Text
8. 8.↵
   2. Brenneis C,
   3. Seppi K,
   4. Schocke MF, et al

   . Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003;18:1132–38

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Schulz JB,
   3. Skalej M,
   4. Wedekind D, et al

   . Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65–74

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Schocke MF,
    3. Seppi K,
    4. Esterhammer R, et al

    . Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575–80

    CrossRef
11. 11.↵
    2. Nicoletti G,
    3. Lodi R,
    4. Condino F, et al

    . Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679–87

    Abstract/FREE Full Text
12. 12.↵
    2. Ito M,
    3. Watanabe H,
    4. Kawai Y, et al

    . Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007;78:722–28

    Abstract/FREE Full Text
13. 13.↵
    2. Watanabe H,
    3. Fukatsu H,
    4. Katsuno M, et al

    . Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004;75:103–09

    Abstract/FREE Full Text
14. 14.↵
    2. Berg D,
    3. Godau J,
    4. Walter U

    . Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044–55

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Brooks DJ,
    3. Salmon EP,
    4. Mathias CJ, et al

    . The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539–52

    Abstract/FREE Full Text
16. 16.↵
    2. Antonini A,
    3. Leenders KL,
    4. Vontobel P, et al

    . Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187–95

    Abstract/FREE Full Text
17. 17.↵
    2. Brücke T,
    3. Asenbaum S,
    4. Pirker W, et al

    . Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24

    CrossRefPubMed
18. 18.↵
    2. Benamer TS,
    3. Patterson J,
    4. Grosset DG, et al

    . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³I]-FP-CIT SPECT imaging: the [¹²³I]-FP-CIT study group. Mov Disord 2000;15:503–10

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Nocker M,
    3. Seppi K,
    4. Donnemiller E, et al

    . Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]beta-CIT SPECT. Eur J Nucl Med Mol Imaging 2012;39:1012–20

    CrossRefPubMed
20. 20.↵
    2. Seeman P,
    3. Niznik H

    . Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4:2737–44

    Abstract
21. 21.↵
    2. Costa DC,
    3. Verhoeff NP,
    4. Cullum ID, et al

    . In vivo characterisation of 3-iodo-6-methoxybenzamide ¹²³I in humans. Eur J Nucl Med 1990;16:813–16

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Ichise M,
    3. Ballinger JR,
    4. Vines D, et al

    . Simplified quantification and reproducibility studies of dopamine D₂-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997;38:31–37

    Abstract/FREE Full Text
23. 23.↵
    2. Churchyard A,
    3. Donnan GA,
    4. Hughes A, et al

    . Dopa resistance in multiple-system atrophy: loss of postsynaptic D₂ receptors. Ann Neurol 1993;34:219–26

    CrossRefPubMedWeb of Science
24. 24.↵
    2. van Royen E,
    3. Verhoeff NPLG,
    4. Speelman JD, et al

    . Multiple system atrophy and progressive supranuclear palsy: diminished striatal D₂-receptor activity demonstrated by ¹²³I-IBZM single photon emission computed tomography. Arch Neurol 1993;50:513–16

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Schwarz J,
    3. Tatsch K,
    4. Gasser T, et al

    . 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998;13:16–19

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Yekhlef F,
    3. Ballan G,
    4. Macia F, et al

    . Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003;110:151–69

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Quattrone A,
    3. Nicoletti G,
    4. Messina D, et al

    . MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214–21

    CrossRefPubMed
28. 28.↵
    2. Brenneis C,
    3. Seppi K,
    4. Schocke MF, et al

    . Voxel-based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004;75:246–49

    Abstract/FREE Full Text
29. 29.↵
    2. Price S,
    3. Paviour D,
    4. Scahill R, et al

    . Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004;23:663–69

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Blain CR,
    3. Barker GJ,
    4. Jarosz JM, et al

    . Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006;67:2199–205

    CrossRef
31. 31.↵
    2. Seppi K,
    3. Schocke MF,
    4. Esterhammer R, et al

    . Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the Parkinson variant of multiple system atrophy. Neurology 2003;60:922–27

    CrossRef
32. 32.↵
    2. Brooks DJ,
    3. Ibanez V,
    4. Sawle GV, et al

    . Striatal D² receptors in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with¹¹C-raclopride and positron emission tomography. Ann Neurol 1992;31:184–92

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Garraux G,
    3. Salmon E,
    4. Degueldre C, et al

    . Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage 1999;10:149–62

    CrossRefPubMed
34. 34.↵
    2. Antonini A,
    3. Benti R,
    4. De NR, et al

    . ¹²³I-Ioflupane SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Neurol Sci 2003;24:149–50

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Vlaar AM,
    3. van Kroonenburgh MJ,
    4. Kessels AG, et al

    . Meta-analysis of the literature on the diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;1:27
36. 36.↵
    2. Koch W,
    3. Hamann C,
    4. Radau PE, et al

    . Does combined imaging of the pre-and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging 2007;34:1265–73

    CrossRefPubMed
37. 37.↵
    2. Kim YJ,
    3. Ichise M,
    4. Ballainger JR, et al

    . Combination of dopamine transporter and D₂ receptor SPECT in the diagnostic evaluation of PD, MSA and PSP. Mov Disord 2002;2:303–12
38. 38.↵
    2. Vlaar AM,
    3. de Nijs T,
    4. Kessels AG, et al

    . Diagnostic value of ¹²³I-Ioflupane and ¹²³I-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes. Eur Neurol 2008;59:258–66

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Plotkin M,
    3. Amthauer H,
    4. Klaffke S, et al

    . Combined [¹²³I]-FPCIT and [¹²³I]-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677–92

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Südmeyer M,
    3. Antke C,
    4. Zizek T, et al

    . Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011;52:733–40

    Abstract/FREE Full Text
41. 41.↵
    2. Gröschel K,
    3. Hauser TK,
    4. Luft A, et al

    . Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004;21:714–24

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Boxer AL,
    3. Geschwind MD,
    4. Belfor N, et al

    . Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63:81–86

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Erbetta A,
    3. Mandelli ML,
    4. Savoiardo M, et al

    . Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am J Neuroradiol 2009;30:1482–87

    Abstract/FREE Full Text
44. 44.↵
    2. Klaffke S,
    3. Kuhn AA,
    4. Plotkin M, et al

    . Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006;21:1724–27

    CrossRefPubMed
45. 45.↵
    2. Cilia R,
    3. Rossi C,
    4. Frosini D, et al

    . Dopamine transporter SPECT imaging in corticobasal syndrome. PLoS One 2011;6:e18301

    CrossRefPubMed
46. 46.↵
    2. Pirker S,
    3. Perju-Dumbrava L,
    4. Kovacs GG, et al

    . Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration. Parkinsonism Relat Disord 2013;19:222–26

    CrossRefPubMed
47. 47.↵
    2. Stevens T,
    3. Livingston G,
    4. Kitchen G, et al

    . Islington study of dementia subtypes in the community. Br J Psychiatry 2002;180:270–76

    Abstract/FREE Full Text
48. 48.↵
    2. Ala TA,
    3. Yang KH,
    4. Sung JH, et al

    . Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16–21

    Abstract/FREE Full Text
49. 49.↵
    2. McKeith I,
    3. Fairbairn A,
    4. Perry R, et al

    . Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673–78

    Abstract/FREE Full Text
50. 50.↵
    2. Ditter SM,
    3. Mirra SS

    . Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754–60

    CrossRef
51. 51.↵
    2. Barber R,
    3. Gholkar A,
    4. Scheltens P, et al

    . Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52:1153–58

    CrossRef
52. 52.↵
    2. Whitwell JL,
    3. Weigand SD,
    4. Shiung MM, et al

    . Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007;130:708–19

    Abstract/FREE Full Text
53. 53.↵
    2. Kenny ER,
    3. Burton EJ,
    4. O'Brien JT

    . A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with Lewy bodies: a comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008;26:218–25

    CrossRefPubMed
54. 54.↵
    2. Firbank MJ,
    3. Blamire AM,
    4. Krishnan MS, et al

    . Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. Psychiatry Res 2007;155:135–45

    CrossRefPubMed
55. 55.↵
    2. Lobotesis K,
    3. Fenwick JD,
    4. Phipps A, et al

    . Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–49

    CrossRef
56. 56.↵
    2. Gilman S,
    3. Koeppe RA,
    4. Little R, et al

    . Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191:S95–S103

    CrossRefPubMedWeb of Science
57. 57.↵
    2. Piggott MA,
    3. Marshall EF,
    4. Thomas N, et al

    . Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449–68

    Abstract/FREE Full Text
58. 58.↵
    2. O'Brien JT,
    3. Colloby S,
    4. Fenwick J, et al

    . Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25

    CrossRefPubMedWeb of Science
59. 59.↵
    2. Zijlmans JC,
    3. Daniel SE,
    4. Hughes AJ, et al

    . Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004;19:630–40

    CrossRefPubMedWeb of Science
60. 60.↵
    2. Forno L

    . Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol (Berl) 1983;62:96–102

    CrossRefPubMedWeb of Science
61. 61.↵
    2. Sjøholm H,
    3. Bratlid T,
    4. Sundsfjord J

    . [¹²³I]-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 2004;173:27–31

    CrossRefPubMed
62. 62.↵
    2. Isaias IU,
    3. Marotta G,
    4. Hirano S, et al

    . Imaging essential tremor. Mov Disord 2010;25:679–86

    CrossRefPubMedWeb of Science
63. 63.↵
    2. Jeon B,
    3. Kim JM,
    4. Jeong JM

    . Dopamine transporter imaging with [¹²³I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60–64

    Abstract/FREE Full Text
64. 64.↵
    2. Borasio GD,
    3. Linke R,
    4. Schwarz J, et al

    . Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 1998;65:263–65

    Abstract/FREE Full Text
65. 65.↵
    2. Ichiba M,
    3. Nakamura M,
    4. Sano A

    . Neuroacanthocytosis update. Brain Nerve 2008;60:635–41

    PubMed